MPO and Myocardial fibrosis: In patients with acute myocardial infarction (MI), treatment with high-dose O3-FA was associated with a reduction of adverse left ventricular remodeling, noninfarct myocardial fibrosis (ST2), and serum biomarkers of systemic and vascular inflammation (MPO, Lp-PLA2) [7].